# Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma

> **NCT07520214** · EARLY_PHASE1 · ENROLLING_BY_INVITATION · sponsor: **Beijing Neurosurgical Institute** · enrollment: 9 (estimated)

## Conditions studied

- Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
- Glioblastom WHO Grade 4

## Interventions

- **BIOLOGICAL:** mRNA vaccine: GV-907、GV-108

## Key facts

- **NCT ID:** NCT07520214
- **Lead sponsor:** Beijing Neurosurgical Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-09-10
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2026-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07520214

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07520214, "Clinical Study on the Safety and Immunogenicity of Specific Cancer Vaccines in Preventing Recurrence of Glioblastoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07520214. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*